Skip to main content
SpringerLink
Log in

Pharmacokinetic Profile of Piroxicam-β-Cyclodextrin

  • Published:
Drug Investigation Aims and scope Submit manuscript

Summary

Bioavailability and pharmacokinetic studies with piroxicam-β-cyclodextrin (CHF 1194) showed that absorption of piroxicam administered as a complex is faster than that of piroxicam alone for the oral and rectal routes of administration in rabbits and dogs. This inclusion complex, which has a molar ratio of 1:2.5, produced the optimal absorption of all the combinations tested. CHF 1194 has excellent bioavailability by the 2 routes tested and the kinetics are characterised by a rapid onset of peak plasma concentrations that are greater than those obtained with piroxicam alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Dansions AC, Johnson EL, Keeley FJ, Gryczko Rawsky V. High performance liquid chromatographic analysis of isoxicam in human plasma and urine. Journal of Chromatography 305: 145, 1984

    Article  Google Scholar 

  • Duchêne D, Glomot F, Vaution C. Pharmaceutical applications of cyclodextrins. In Duchêne D (Ed.) Cyclodextrins and their industrial uses, pp. 211–257, Editions de Santé, Paris, 1987

    Google Scholar 

  • Hobbs DC, Twomey TM. Piroxicam pharmacokinetics in man: aspirin and antacid interaction studies. Journal of Clinical Pharmacology 19: 270–281, 1979

    PubMed  CAS  Google Scholar 

  • Hobbs DC, Twomey TM. Metabolism of piroxicam by laboratory animals. Drug Metabolism and Disposition 9: 114–118, 1981

    PubMed  CAS  Google Scholar 

  • Koelle EU, Hengy H, Vollmer KO. Pharmacokinetics of isoxicam in man following oral administration. Arzneimittel-Forschung 33: 528, 1983

    Google Scholar 

  • Pitha J, Szente L, Szejtli J. Molecular encapsulation of drugs by cyclodextrins and congeners. In Bruck SD (Ed.) Controlled drug delivery, Vol. 1, pp. 125–148, CRC Press Inc., Boca Raton, Florida, 1983

    Google Scholar 

  • Richardson CJ, Sharon GR, Blocka KL, Verbeeck RK. High-performance liquid chromatographic analysis of piroxicam and its major metabolite 5′-hydroxypiroxicam in human plasma and urine. Journal of Chromatography 382: 383–385, 1986

    Google Scholar 

  • Schiantarelli P, Acerbi D, Bovis G. Some pharmacokinetic properties and bioavailability by oral and rectal route of piroxicam in rodents and in man. Arzneimittel-Forschung 31: 92, 1981

    PubMed  CAS  Google Scholar 

  • Szejtli J. Cyclodextrins and their inclusion complexes. Akademiai Kiado, Budapest, 1982

    Google Scholar 

  • Szejtli J. Industrial applications of cyclodextrins. In Atwood JL et al. (Eds) Inclusion compounds, Vol. 3, pp. 331–390, Academic Press, London, 1984

    Google Scholar 

  • Uekama K, Otagiri M. Cyclodextrins in drug carrier systems. CRC Critical Reviews in Therapeutic Drug Carrier Systems 3: 1–40, 1986

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chemical and Biopharmaceutical Research Laboratories, Chiesi Farmaceutici SpA, via Palermo 26/A, 43100, Parma, Italy

    D. Acerbi

Authors
  1. D. Acerbi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Acerbi, D. Pharmacokinetic Profile of Piroxicam-β-Cyclodextrin. Drug Invest 2 (Suppl 4), 42–49 (1990). https://doi.org/10.1007/BF03258226

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03258226

Keywords

Search

Navigation